Summary: Purpose: Compulsory generic substitution of antiepileptic drugs (AEDs) may lead to adverse effects in epilepsy patients because seizure recurrence or increased toxicity. The study objectives were (a) quantify and compare the switchback rates from brand‐name AEDs versus non‐AEDs, (b) assess clinical implications switching branded Lamictal lamotrigine (LTG) whether signals exist suggesting outcome worsening. Methods: By using a public‐payer pharmacy‐claims database Ontario, Canada,...

<h3>Objective:</h3> To quantify the clinical and economic burden of uncontrolled epilepsy in patients requiring emergency department (ED) visit or hospitalization. <h3>Methods:</h3> Health insurance claims from a 5-state Medicaid database (1997Q1–2009Q2) 55 self-insured US companies ("employer," 1999Q1 2008Q4) were analyzed. Adult with receiving antiepileptic drugs (AED) selected. Using retrospective matched-cohort design, categorized into cohorts "uncontrolled" (≥2 changes AED therapy, then...

To measure the proportions of patients switching from generic to branded drugs among users antiepileptic (AED) compared other therapeutic areas and investigate medical services utilization associated with lamotrigine.Medical pharmacy claims data Régie de l'Assurance Maladie du Québec database April 1998 July 2006 were used. Patients an epilepsy diagnosis (International Classification Diseases-9 345) treated lamotrigine for >60 90 days before entry date in Quebec (February 1, 2003) selected....

To investigate clinical and economic consequences following generic substitution of one vs multiple generics topiramate (Topamax; Ortho-McNeil Neurologics, Titusville, NJ).Medical pharmacy claims data Régie de l'Assurance-Maladie du Québec from January 2006 to October 2007 were used. Patients with epilepsy treated selected. An open-cohort design was used classify the observation period into periods brand, single-generic, multiple-generic use. One-year generic-switch switchback-to-brand rates...

To evaluate whether generic substitution was associated with any difference in medical resource utilization for 5 widely used antiepileptic drugs (AEDs) the United States.Health insurance claims from PharMetrics Database, representing over 90 health plans between January 2000 and October 2007, were analyzed. Adult patients epilepsy, continuously treated carbamazepine, gabapentin, phenytoin, primidone, or zonisamide, selected. An open-cohort design to classify into mutually exclusive periods...

Generic substitution of antiepileptic drugs (AEDs) may increase pharmacy utilization, thus counterbalancing per-pill savings. The purpose our study was to analyze the economic impact government-mandated switching from branded generic lamotrigine. Patients in a Canadian public claims database using lamotrigine (Lamictal GlaxoSmithKline, UK) 2002 converted 2003 and were observed July March 2006. used for >or=90 days pre-generic entry had >or=1 claim post-generic entry. For period, per-patient...

Background: Generic substitution may not always save health care costs for antiepileptic drugs (AED).Objective: (1) To examine the economic impacts of generic lamotrigine in Canada; and (2) to convert observed Canadian a United States (US) setting.Methods: Health claims from Québec's plan (RAMQ) between 08/2002 07/2006 were analyzed. Patients with ≥ 1 epilepsy claim treated branded (Lamictal) before entry selected. ($/person-year) compared during periods use lamotrigine. Two cost-conversion...

Mapping patient and work flow cost analysis studies can help determine the most efficient effective way of providing health services while still maintaining best standards care. This study used both time motion methodology hospital data to assess contribution staff facility usage overall cancer care during visits a comprehensive centre in Quebec, using metastatic colorectal as model. A workflow diagram was created mapping direct indirect steps involved patient's physician or treatment...

Objectives: To explore the effects of generic substitution antiepileptic drug (AED) topiramate (Topamax in Canada; to convert observed Canadian costs into settings France, Germany, Italy, and United Kingdom (UK); forecast economic impact entry these four European countries. Research design methods: Health claims from Régie de l'assurance maladie du Québec (RAMQ) plan (1/2006–9/2008) IMS data (1998–2008) were used. Patients with epilepsy ≥2 dispensings selected. An open-cohort was used...

Background Smoking is the leading risk factor for preventable morbidity and mortality as a result of heart lung diseases various forms cancer. Reimbursement coverage smoking cessation therapies remains limited in Canada United States despite health economic benefits cessation. Objectives This study aimed to evaluate long-term cost-effectiveness varenicline compared with other interventions using Benefits Cessation on Outcomes (BENESCO) model. Methods Efficacy rates standard course (12 weeks)...

Although varenicline (Champix), a smoking-cessation treatment, was recommended for listing by the Common Drug Review (CDR) in 2007, only one CDR-participating drug insurance plan listed it March 2011 (Saskatchewan). This study estimated economic impact of delays public Canada. Using statistical data and peer-reviewed research, social costs benefits reimbursing were estimated. Flows attempted successful quitters projected over five-year period three scenarios: immediate (2007), one- to...

OBJECTIVES: To model population-wide health and cost impacts of vaporised nicotine products (VNPs) use among Canadian adults 20 years older from 2015-2095. METHODS: A multi-state lifetable was used to project potential changes in life expectancy health-system costs, overall by province/territory. The simulated population divided into 68 cohorts sex, ethnicity, 5-year age groups. Each year, individuals could either remain their current state, or transition one six smoking/vaping states. Input...